National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Alirocumab (Praluent®)

Praluent® is indicated for both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.

Rapid Review

Commenced Completed Outcome
13/10/2015 02/11/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
04/01/2016  06/06/2017 Reimbursement Not Recommended


Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.

The HSE has re-commissioned a full HTA for this product as of 20th March 2018
Full pharmacoeconomic assessment re-commissioned by HSE 20/03/2018
Pre-submission consultation with Applicant 08/10/2018
Submission received from Applicant 27/02/2019

The HSE has approved reimbursement following confidential price negotiations. April 2021